Fucoidan-low molecular weight - Fournier

Drug Profile

Fucoidan-low molecular weight - Fournier

Alternative Names: Low molecular weight fucoidan - Fournier

Latest Information Update: 24 Sep 2007

Price : $50

At a glance

  • Originator Fournier Pharma
  • Class Antithrombotics; Polysaccharides
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 23 Dec 1999 Fucoidan-low molecular weight - Fournier is available for licensing (m.hubert@fournier.fr)
  • 23 Dec 1999 Fucoidan-low molecular weight - Fournier is available for licensing (http://www.groupe-fournier.com/english/)
  • 08 Jun 1999 Preclinical development for Thrombosis in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top